6854-08-6

Usage

Uses

Used in Pharmaceutical Development:
THA-9-carbaldehyde is utilized as a key component in the development of pharmaceutical drugs due to its demonstrated biological activities. Its antitumor properties make it a candidate for cancer treatment, while its antibacterial and antifungal characteristics suggest potential applications in antimicrobial therapies.
Used in Photodynamic Therapy:
In the medical field, THA-9-carbaldehyde is used as a potential photosensitizer for photodynamic therapy, a technique that involves the use of light to activate a drug to kill cancer cells. Its ability to absorb light and generate reactive oxygen species makes it a promising agent for this treatment modality.
Used in Material Synthesis:
THA-9-carbaldehyde is employed as a building block in the synthesis of new materials, contributing to the advancement of material science by providing a foundation for the creation of novel compounds with unique properties.
Used in Chemical Compound Development:
As a precursor in chemical compound development, THA-9-carbaldehyde is used to synthesize a variety of new chemical entities, expanding the scope of chemical research and potentially leading to the discovery of new drugs and materials with specific applications across various industries.

InChI:InChI=1/C14H13NO/c16-9-12-10-5-1-3-7-13(10)15-14-8-4-2-6-11(12)14/h1,3,5,7,9H,2,4,6,8H2

Upstream product

• 70254-44-3 2,4-dihydroxyquinoline 
• 14944-78-6 3,3-Dichloro-1H-quinoline-2,4-dione 
• 2721-49-5 1-(2-amino-phenyl)-2,2-dimethoxy-ethanone 
• 6760-17-4 9-dimethoxymethyl-1,2,3,4-tetrahydro-acridine 
• 38186-54-8 1,2,3,4-tetrahydro-9-acridinecarboxylic acid 
• 55618-86-5 methyl-[(1,2,3,4-tetrahydro-9-yl)acridine]carboxylate 

Downstream Products

• 1426584-63-5 C₂₇H₂₇N₂O⁽¹⁺⁾*Br^(1-) 

Relevant academic research and scientific papers

ORGANIC ELECTROCHROMIC MATERIALS HAVING HIGH TRANSPARENCY AND HIGH CONTRAST IN THE VISIBLE RANGE

The present invention relates to electrochromic polymers, obtained by polymerization of monomers. The present invention further relates to monomers of general formula (I) or (II), wherein A and B are specific functional groups selected among the following: -C=0, -C=S, - 0(C=0), -0(C=S), -0(C=0)0, -(C=0)0, -(C=S)0, -(C=S)S, -(C=0)N, -(C=S)N, -SO, - S02, or, as an alternative, any linear or branched alkylic chain or a glycolic chain; wherein R and R' are linear or branched alkylic chains or glycolic chains, and wherein W is a monodisperse electrochromic derivative of general formula (III), wherein Het-1 and Het-2 are specific heterocyclic groups, and wherein π represents one of the following: a double bond, a triple bond or a plurality of double or triple bonds conjugated in a number n, n being equal to 2 or 3 or, for example, a benzenic ring or a thiophenic ring; X represents one of the following elements: O, S, Se; wherein R2, R3 and R4 are substituents; and wherein m is equal to 0, 4, 5 or 6. The present invention also relates to electrochromic panels and electrochromic ophthalmic lenses, comprising polymers in accordance with the present invention.

Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors

Tacrine heterobivalent ligands were designed as novel and reversible inhibitors of cholinesterases. On the basis of the investigation of the active site gorge topology of butyrylcholinesterase (BuChE) and acetylcholinesterase (AChE) and by using flexible docking procedures, molecular modeling studies formulated the hypothesis of extra interaction sites in the active gorge of hBuChE, namely, a mid-gorge interaction site and a peripheral interaction site. The design strategy led to novel BuChE inhibitors, balancing potency and selectivity. Among the compounds identified, the heterobivalent ligand 4m, containing an amide nitrogen and a sulfur atom at the 8-membered tether level, is one of the most potent and selective BuChE inhibitors described to date. The novel inhibitors, bearing postulated key features, validated the hypothesis of the presence of extra interaction sites within the hBuChE active site gorge.